Trial reportJournal of clinical oncology : official journal of the American Society of Clinical Oncology2025
INTEGRATE IIa Phase III Study: Regorafenib for Refractory Advanced Gastric Cancer.
Trial report in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Neoadjuvant Therapy for Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma: Current Status, Challenges, and Future Perspectives.Cancer medicine · 2026Pooled it
- Tyrosine kinase inhibitors and survival in advanced or metastatic gastric cancer: a systematic review and meta-analysis.Frontiers in oncology · 2026Pooled it
- Health-related quality-of-life outcomes with regorafenib in advanced gastric and esophagogastric junction cancer: results from the INTEGRATE trials.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2025Trial
- INTEGRATE pooled phase 2/3 results are robust to postprogression switching and the winner's curse.JNCI cancer spectrum · 2025Trial
- Trial
- In search of the best perioperative treatment for gastroesophageal cancer: is there a role for antiangiogenesis?Journal of gastrointestinal oncology · 2026Article
- Development of systemic chemotherapy starting from comparison with best supportive care: commentary on the INTEGRATE IIa phase III study.Journal of gastrointestinal oncology · 2026Article
- Beyond LEAP-015: the ongoing challenge of vascular endothelial growth factor inhibition in gastric cancer.Journal of gastrointestinal oncology · 2026Article
- Regorafenib in refractory gastric cancer: modest median, meaningful milestone.Journal of gastrointestinal oncology · 2026Article
- DAWN trial: a prospective, multicenter, single-arm phase II study of neoadjuvant disitamab vedotin (RC48) in combination with adebrelimab, apatinib, and S-1 for locally advanced HER2-positive gastric cancer.Journal of gastrointestinal oncology · 2026Article
- A dimer peptide ligand of vascular endothelial growth factor slows the progression of human gastric tumors in mouse xenografts.PloS one · 2026Article
- Potential of regorafenib in late-line treatment for refractory advanced gastric cancer.Journal of gastrointestinal oncology · 2025Article
- Development and validation of a prognostic model incorporating patient reported outcomes for advanced gastric and esophageal carcinoma (AGOC) using individual patient data from two AGITG randomized clinical trials.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2025Article
- Perioperative Immune Checkpoint Inhibitors for the Treatment of Locally Advanced Gastric and Gastroesophageal Junction Cancer: Current Status and Future Prospects.Current treatment options in oncology · 2025Review
- Clinical advances and challenges of anti-angiogenic targeted therapy in gastric cancer.Frontiers in oncology · 2025Review
- Multimodal therapeutic strategies against gastric cancer: from conventional treatments to tumor microenvironment targeting.Frontiers in immunology · 2025Review
- First-line maintenance strategies and later-line options in patients with advanced gastroesophageal adenocarcinoma.Therapeutic advances in medical oncology · 2025Review
- Nab-paclitaxel combined with cadonilimab (AK104) as second-line treatment for advanced gastric cancer: protocol for a phase II prospective, multicenter, single-arm clinical trial.Frontiers in immunology · 2025Article
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
Authors and funding
21 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTreatment options for refractory advanced gastric and esophagogastric junction cancer (AGOC) are limited. Regorafenib, an oral multikinase inhibitor, prolonged progression-free survival (PFS) versus placebo in the INTEGRATE I phase II trial. INTEGRATE IIa was designed to examine whether regorafenib improved overall survival (OS).
methodsA double-blind placebo-controlled phase III trial compared regorafenib and best supportive care (BSC) versus placebo and BSC for participants with confirmed evaluable metastatic/advanced AGOC who failed ≥two prior therapies on a 2:1 random assignment, stratified by tumor location, geographic region (Asia
resultsINTEGRATE IIa enrolled 251 participants: 157 from Asia and 94 from rest of world and 169 received regorafenib and 82 received placebo. No significant heterogeneity was observed between INTEGRATE I and INTEGRATE IIa studies on OS. Pooled OS analysis hazard ratio (HR) was 0.70 (95% CI, 0.56 to 0.87;
conclusionRegorafenib improves survival compared with placebo in refractory AGOC.
Indexed as
Identifiers
39365958What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.